# A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

Source: https://onco.cc/trials/nct07243340/  
OnCo record `nct07243340` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Herpes Virus C5252 Injection in glioma & glioblastoma, run by ImmVira Pharma Co. Ltd, now recruiting.

## Summary

A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor is a phase 1/2 interventional study registered as NCT07243340 by ImmVira Pharma Co. Ltd, with 36 participants planned, started 2026-04-03 and due to reach its primary completion in 2027-12-15. Interventions recorded: Herpes Virus C5252 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07243340
- Phase: 1/2
- Setting: A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor
- Sponsor: ImmVira Pharma Co. Ltd
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07243340: https://clinicaltrials.gov/study/NCT07243340

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [ImmVira Pharma](https://onco.cc/companies/immvira-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07243340.json